☰

Mickael Decressac, Ph.D - Publications

Affiliations: 
Wallenberg Neuroscience Center Lund University, Lund, Skåne län, Sweden 
Area:
Parkinson's disease
Tree Info Grants Similar researchers PubMed Report error

24 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2016 Tamburrino A, Decressac M. Aged and Diseased Neurons Get Lost in Transport. Trends in Neurosciences. PMID 26970902 DOI: 10.1016/J.Tins.2016.02.007  0.43
2016 Dehay B, Decressac M, Bourdenx M, Guadagnino I, Fernagut PO, Tamburrino A, Bassil F, Meissner WG, Bezard E. Targeting α-synuclein: Therapeutic options. Movement Disorders : Official Journal of the Movement Disorder Society. PMID 26926119 DOI: 10.1002/Mds.26568  0.515
2016 Tozzi A, de Iure A, Bagetta V, Tantucci M, Durante V, Quiroga-Varela A, Costa C, Di Filippo M, Ghiglieri V, Latagliata EC, Wegrzynowicz M, Decressac M, Giampà C, Dalley JW, Xia J, et al. Alpha-Synuclein Produces Early Behavioral Alterations via Striatal Cholinergic Synaptic Dysfunction by Interacting With GluN2D N-Methyl-D-Aspartate Receptor Subunit. Biological Psychiatry. 79: 402-14. PMID 26392130 DOI: 10.1016/J.Biopsych.2015.08.013  0.476
2015 Tamburrino A, Churchill MJ, Wan OW, Colino-Sanguino Y, Ippolito R, Bergstrand S, Wolf DA, Herz NJ, Sconce MD, Björklund A, Meshul CK, Decressac M. Cyclosporin promotes neurorestoration and cell replacement therapy in pre-clinical models of Parkinson's disease. Acta Neuropathologica Communications. 3: 84. PMID 26666562 DOI: 10.1186/S40478-015-0263-6  0.531
2015 Volakakis N, Tiklova K, Decressac M, Papathanou M, Mattsson B, Gillberg L, Nobre A, Björklund A, Perlmann T. Nurr1 and Retinoid X Receptor Ligands Stimulate Ret Signaling in Dopamine Neurons and Can Alleviate α-Synuclein Disrupted Gene Expression. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 35: 14370-85. PMID 26490873 DOI: 10.1523/Jneurosci.1155-15.2015  0.522
2013 Decressac M, Volakakis N, Björklund A, Perlmann T. NURR1 in Parkinson disease--from pathogenesis to therapeutic potential. Nature Reviews. Neurology. 9: 629-36. PMID 24126627 DOI: 10.1038/Nrneurol.2013.209  0.63
2013 Decressac M, Björklund A. mTOR inhibition alleviates L-DOPA-induced dyskinesia in parkinsonian rats. Journal of Parkinson's Disease. 3: 13-7. PMID 23938307 DOI: 10.3233/Jpd-120155  0.458
2013 Decressac M, Björklund A. TFEB: Pathogenic role and therapeutic target in Parkinson disease. Autophagy. 9: 1244-6. PMID 23715007 DOI: 10.4161/Auto.25044  0.626
2013 Decressac M, Mattsson B, Weikop P, Lundblad M, Jakobsson J, Björklund A. TFEB-mediated autophagy rescues midbrain dopamine neurons from α-synuclein toxicity. Proceedings of the National Academy of Sciences of the United States of America. 110: E1817-26. PMID 23610405 DOI: 10.1073/Pnas.1305623110  0.684
2013 Kadkhodaei B, Alvarsson A, Schintu N, Ramsköld D, Volakakis N, Joodmardi E, Yoshitake T, Kehr J, Decressac M, Björklund A, Sandberg R, Svenningsson P, Perlmann T. Transcription factor Nurr1 maintains fiber integrity and nuclear-encoded mitochondrial gene expression in dopamine neurons. Proceedings of the National Academy of Sciences of the United States of America. 110: 2360-5. PMID 23341612 DOI: 10.1073/Pnas.1221077110  0.522
2012 Decressac M, Kadkhodaei B, Mattsson B, Laguna A, Perlmann T, Björklund A. α-Synuclein-induced down-regulation of Nurr1 disrupts GDNF signaling in nigral dopamine neurons. Science Translational Medicine. 4: 163ra156. PMID 23220632 DOI: 10.1126/Scitranslmed.3004676  0.635
2012 Decressac M, Barker RA. Neuropeptide Y and its role in CNS disease and repair. Experimental Neurology. 238: 265-72. PMID 23022456 DOI: 10.1016/J.Expneurol.2012.09.004  0.322
2012 Decressac M, Mattsson B, Björklund A. Comparison of the behavioural and histological characteristics of the 6-OHDA and α-synuclein rat models of Parkinson's disease. Experimental Neurology. 235: 306-15. PMID 22394547 DOI: 10.1016/J.Expneurol.2012.02.012  0.591
2012 Lundblad M, Decressac M, Mattsson B, Björklund A. Impaired neurotransmission caused by overexpression of α-synuclein in nigral dopamine neurons. Proceedings of the National Academy of Sciences of the United States of America. 109: 3213-9. PMID 22315428 DOI: 10.1073/Pnas.1200575109  0.454
2012 Decressac M, Mattsson B, Lundblad M, Weikop P, Björklund A. Progressive neurodegenerative and behavioural changes induced by AAV-mediated overexpression of α-synuclein in midbrain dopamine neurons. Neurobiology of Disease. 45: 939-53. PMID 22182688 DOI: 10.1016/J.Nbd.2011.12.013  0.655
2012 Decressac M, Pain S, Chabeauti PY, Frangeul L, Thiriet N, Herzog H, Vergote J, Chalon S, Jaber M, Gaillard A. Neuroprotection by neuropeptide Y in cell and animal models of Parkinson's disease. Neurobiology of Aging. 33: 2125-37. PMID 21816512 DOI: 10.1016/J.Neurobiolaging.2011.06.018  0.589
2011 Decressac M, Ulusoy A, Mattsson B, Georgievska B, Romero-Ramos M, Kirik D, Björklund A. GDNF fails to exert neuroprotection in a rat α-synuclein model of Parkinson's disease. Brain : a Journal of Neurology. 134: 2302-11. PMID 21712347 DOI: 10.1093/Brain/Awr149  0.615
2011 Thiriet N, Gennequin B, Lardeux V, Chauvet C, Decressac M, Janet T, Jaber M, Solinas M. Environmental enrichment does not reduce the rewarding and neurotoxic effects of methamphetamine. Neurotoxicity Research. 19: 172-82. PMID 20143198 DOI: 10.1007/S12640-010-9158-2  0.389
2011 Decressac M, Wright B, David B, Tyers P, Jaber M, Barker RA, Gaillard A. Exogenous neuropeptide Y promotes in vivo hippocampal neurogenesis. Hippocampus. 21: 233-8. PMID 20095007 DOI: 10.1002/Hipo.20765  0.34
2010 Ulusoy A, Decressac M, Kirik D, Björklund A. Viral vector-mediated overexpression of α-synuclein as a progressive model of Parkinson's disease. Progress in Brain Research. 184: 89-111. PMID 20887871 DOI: 10.1016/S0079-6123(10)84005-1  0.697
2010 Decressac M, Wright B, Tyers P, Gaillard A, Barker RA. Neuropeptide Y modifies the disease course in the R6/2 transgenic model of Huntington's disease. Experimental Neurology. 226: 24-32. PMID 20673761 DOI: 10.1016/J.Expneurol.2010.07.022  0.504
2010 Besnard S, Decressac M, Denise P. In-vivo deep brain recordings of intranigral grafted cells in a mouse model of Parkinson's disease. Neuroreport. 21: 485-9. PMID 20405544 DOI: 10.1097/Wnr.0B013E328337F4Ca  0.402
2009 Gaillard A, Decressac M, Frappé I, Fernagut PO, Prestoz L, Besnard S, Jaber M. Anatomical and functional reconstruction of the nigrostriatal pathway by intranigral transplants. Neurobiology of Disease. 35: 477-88. PMID 19616502 DOI: 10.1016/J.Nbd.2009.07.003  0.416
2009 Decressac M, Prestoz L, Veran J, Cantereau A, Jaber M, Gaillard A. Neuropeptide Y stimulates proliferation, migration and differentiation of neural precursors from the subventricular zone in adult mice. Neurobiology of Disease. 34: 441-9. PMID 19285132 DOI: 10.1016/J.Nbd.2009.02.017  0.37
Show low-probability matches.